.jpeg)
{{ variable.name }}
Anastrozol (anastrozol) Instructions
Common name: Anastrozole
Trade name: Arimidex
All names: Arimidex, anastrozol, anastrozole, Arimidex, anastrozole
Indications:
Applicable to the treatment of advanced breast cancer in postmenopausal women. For patients with negative estrogen receptors and a positive clinical response to tamoxifen, this product may be considered.
Applicable to adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women.
It is suitable for adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women who have received 2 to 3 years of tamoxifen adjuvant therapy.
Usage and dosage:
Once a day, 1 mg each time.
You can take it in the morning or evening, before or after meals, and swallow the whole pill.
Serious Adverse Reactions:
Skin reactions, such as lesions, ulcers, or blisters
Allergic reactions such as swelling of the face, lips, tongue, or throat (may cause difficulty swallowing or breathing)
Changes in liver function blood tests, including inflammation of the liver, symptoms may include general discomfort, with or without jaundice, liver pain, or liver swelling
Common adverse reactions in women (≥10%):< br>Hot flashes, fatigue, arthritis, pain, arthralgia, hypertension, depression, nausea and vomiting, rash, osteoporosis, fracture, back pain, insomnia, headache, bone pain, peripheral edema, worsening cough, dyspnea, pharyngitis and lymphedema
Adverse reactions to discontinuation of treatment in the trial (>0.1%):
Hot flashes
Contraindications:
Allergy to anastrozole or any component of the formulation.
Contraindicated for pregnant women.
Premenopausal women.
Patients with severe renal impairment (creatinine clearance less than 20ml/min).
Notes:
Bone Effects: Results from the 12-month and 24-month bone studies of the ATAC trial showed that patients receiving Arimidex experienced an average decrease in lumbar spine and total hip bone mineral density (BMD) compared with baseline. Patients treated with tamoxifen had a mean increase in lumbar spine and total hip BMD compared with baseline. Consider bone mineral density monitoring in patients treated with anastrozole.
Cholesterol: During the ATAC trial, increased serum cholesterol was reported in patients taking anastrozole compared with those taking tamoxifen (9% vs. 3.5%, respectively).
Ischemic cardiovascular events: The incidence of ischemic cardiovascular events was increased in the ATAC trial among women with previous ischemic heart disease. Consider the risks and benefits of anastrozole in patients with preexisting ischemic heart disease.
If you have heart disease, osteoporosis, blood circulation problems, a history of stroke, thromboembolism, severe liver disease, or patients who have not completed menopause, doctors need to use medication with caution in these situations, so you should inform your doctor before using this medicine.
The concentration of anastrozole in the body will be affected by other drugs. If the concentration is too high, it will cause unnecessary side effects; if the concentration is too low, it will not be effective. Before taking this medication, you should make a list of all medications you take, including prescription and over-the-counter medications, especially those containing hormones. If you want to add or remove any medicine while using the medicine, you should obtain the permission of your doctor in advance. Other estrogen-containing drugs may reduce the effectiveness of this drug and should not be used with these drugs.
Anastrozole may cause liver inflammation and affect the results of blood and liver function tests. Therefore, doctors need to frequently test the effects of drugs on patients' livers. Patients should follow the doctor's instructions and go to the hospital or clinic regularly for blood tests. If you often feel tired, have yellow skin, or feel pain in your upper right abdomen and other symptoms of liver problems while taking this medicine, you should notify your doctor immediately.
Storage:
Store at controlled room temperature, 20-25°C (68-77°F)
Avoid light and keep sealed
Mechanism of action:
In postmenopausal women, estrogen mainly comes from the action of aromatase, which converts adrenal androgens (mainly androstenedione and testosterone) into estrone and estradiol. Therefore, estrogen biosynthesis in peripheral tissues and cancer tissue itself can be inhibited by specifically inhibiting aromatase.
Anastrozole is a selective non-steroidal aromatase inhibitor. Significantly reduces serum estradiol concentrations without significant effects on the formation of adrenocortical hormones or aldosterone.